1. Peroxisome proliferator activated receptors and stroke

   • Jean-Charles Fruchart
   • Régis Bordet
   • Patrick Duriez

   Invited Commentary Pages: 331 - 332

2. Literature alert

   Announcement Pages: 334 - 335

3. Clinical trials report

   • Peter P. Toth

   OriginalPaper Pages: 339 - 340

4. C-reactive protein and risk of cardiovascular disease: Evidence and clinical application

   • Paul M. Ridker
   • Shari S. Bassuk
   • Peter P. Toth

   OriginalPaper Pages: 341 - 349

5. Microalbuminuria and diabetic cardiovascular disease

   • Richard J. MacIsaac
   • Mark E. Cooper

   OriginalPaper Pages: 350 - 357

6. Implications of the heart protection study for reducing coronary events in high-risk patients

   • William Virgil Brown
   • Warren Davis
   • Matthey Harris

   OriginalPaper Pages: 358 - 363

7. The insulin resistance syndrome

   • Gerald M. Reaven

   OriginalPaper Pages: 364 - 371

8. Isoprenoid metabolism and the pleiotropic effects of statins

   • Ulrich Laufs
   • James K. Liao

   OriginalPaper Pages: 372 - 378

9. Evidence-based management of dyslipidemias in women

   • John C. LaRosa

   OriginalPaper Pages: 379 - 385

10. Reverse cholesterol transport: High-density lipoprotein’s magnificent mile

    • Peter P. Toth

    OriginalPaper Pages: 386 - 393

11. In-hospital initiation of statin therapy in patients with acute coronary events

    • Gregg C. Fonarow

    OriginalPaper Pages: 394 - 402

12. Toxicity of antilipidemic agents: Facts and fictions

    • Antonios M. Xydakis
    • Peter H. Jones

    OriginalPaper Pages: 403 - 410

13. Magnetic resonance imaging of coronary atherosclerosis

    • Zahi A. Fayad
    • Robin P. Choudhury
    • Valentin Fuster

    OriginalPaper Pages: 411 - 417

14. Niacin: A powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events

    • Michael H. Davidson

    OriginalPaper Pages: 418 - 422

15. Web alert

    Announcement Pages: 423 - 423